Journal of Clinical Oncology, Vol 16, 255-260, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

DJ Vaughn, SB Malkowicz, B Zoltick, R Mick, P Ramchandani, C Holroyde, B Armstead, K Fox and A Wein
University of Pennsylvania Cancer Center/Penn Cancer Clinical Trials Group, Philadelphia 19104, USA. djv@mail.med.upenn.edu

PURPOSE: To determine the toxicity and efficacy of an outpatient regimen of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium. PATIENTS AND METHODS: Patients received paclitaxel 150 to 225 mg/m2 over 3 hours followed by carboplatin (targeted area under the concentration-time curve [AUC], 6 mg/mL x min) every 3 weeks. During phase I accrual, 16 patients were treated; 17 additional patients were enrolled at the phase II dose. The median age was 70 years (range, 47 to 82). The median serum creatinine concentration was 1.1 mg/dL (range, 0.7 to 2.7) and the median estimated creatinine clearance was 52 mL/min (range, 24 to 110). RESULTS: During phase I accrual, the maximum-tolerated dose (MTD) of the regimen was not defined. Phase II accrual occurred at the paclitaxel 225 mg/m2 dose level. A total of 156 cycles were administered. The median number of cycles received was five (range, one to eight). Sensorimotor neuropathy was the principal nonhematologic toxicity. Significant granulocytopenia was common, but significant thrombocytopenia was not. Objective responses were demonstrated at all dose levels. At the phase II dose (paclitaxel 225 mg/m2 followed by carboplatin at AUC 6 mg/mL x min), the objective response rate was 50% (95% confidence interval [CI], 28% to 72%). CONCLUSION: Paclitaxel plus carboplatin is an active and tolerable outpatient treatment for patients with advanced carcinoma of the urothelium. The ability to administer this combination over multiple cycles even to patients with advanced age and abnormal renal function makes it well suited for this patient population. Confirmatory trials of this regimen are ongoing.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Kamat, G. Sethi, and B. B. Aggarwal Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-{kappa}B and nuclear factor-{kappa}B-regulated gene products in IFN-{alpha}-sensitive and IFN-{alpha}-resistant human bladder cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1022 - 1030. [Abstract] [Full Text] [PDF]

				R Sawhney, D Bourgeois, and U. Chaudhary Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead Ann. Onc., September 1, 2006; 17(9): 1360 - 1369. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]

				M. D. Galsky The Role of Taxanes in the Management of Bladder Cancer Oncologist, November 1, 2005; 10(10): 792 - 798. [Abstract] [Full Text] [PDF]

				K. A. Gelmon, D. Stewart, K. N. Chi, S. Chia, C. Cripps, S. Huan, S. Janke, D. Ayers, D. Fry, J. A. Shabbits, et al. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131 Ann. Onc., July 1, 2004; 15(7): 1115 - 1122. [Abstract] [Full Text] [PDF]

				A. Bamias, Ch. Deliveliotis, G. Fountzilas, D. Gika, A. Anagnostopoulos, M.P. Zorzou, E. Kastritis, C. Constantinides, P. Kosmidis, and M.A. Dimopoulos Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group J. Clin. Oncol., June 1, 2004; 22(11): 2150 - 2154. [Abstract] [Full Text] [PDF]

				A. M. Kamat, T. Karashima, D. W. Davis, L. Lashinger, M. Bar-Eli, R. Millikan, Y. Shen, C. P. N. Dinney, and D. J. McConkey The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo Mol. Cancer Ther., March 1, 2004; 3(3): 279 - 290. [Abstract] [Full Text]

				C. J. Henry, D. L. McCaw, S. E. Turnquist, J. W. Tyler, L. Bravo, S. Sheafor, R. C. Straw, W. S. Dernell, B. R. Madewell, L. Jorgensen, et al. Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 906 - 911. [Abstract] [Full Text] [PDF]

				C. N. Sternberg, P. H.M. de Mulder, J. H. Schornagel, C. Theodore, S. D. Fossa, A. T. van Oosterom, F. Witjes, M. Spina, C. J. van Groeningen, C. de Balincourt, et al. Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924 J. Clin. Oncol., May 15, 2001; 19(10): 2638 - 2646. [Abstract] [Full Text] [PDF]

				M. Hussain, U. Vaishampayan, W. Du, B. Redman, and D. C. Smith Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer J. Clin. Oncol., May 1, 2001; 19(9): 2527 - 2533. [Abstract] [Full Text] [PDF]

				E. J. Small, D. Lew, B. G. Redman, D. P. Petrylak, N. Hammond, H. M. Gross, J. A. Eastham, and E. D. Crawford Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point J. Clin. Oncol., July 1, 2000; 18(13): 2537 - 2544. [Abstract] [Full Text] [PDF]

				K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643. [Abstract] [Full Text]

				P. M. Dodd, J. A. McCaffrey, S. Hilton, M. Mazumdar, H. Herr, W. K. Kelly, E. Icasiano, M. G. Boyle, and D. F. Bajorin Phase I Evaluation of Sequential Doxorubicin Gemcitabine Then Ifosfamide Paclitaxel Cisplatin for Patients With Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract J. Clin. Oncol., February 14, 2000; 18(4): 840 - 840. [Abstract] [Full Text] [PDF]

				D. F. Bajorin, P. M. Dodd, M. Mazumdar, M. Fazzari, J. A. McCaffrey, H. I. Scher, H. Herr, G. Higgins, and M. G. Boyle Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy J. Clin. Oncol., October 1, 1999; 17(10): 3173 - 3181. [Abstract] [Full Text] [PDF]